Lenacapavir (LEN)

A New PrEP Option for HIV Prevention

A few days ago on Instagram, I came across a WHO post recommending lenacapavir as an additional PrEP option for HIV prevention, alongside a report noting that about 1.3 million people acquired HIV in 2024. I couldn’t help but imagine how drastically these numbers might have been reduced if this long-acting ART regimen had been widely available and people were aware of it. And that post caught my attention, because lenacapavir represents one of the most exciting advancements in HIV prevention technology today.

(Source: WHO page on Instagram)

Unlike traditional PrEP that depends heavily on strict daily adherence, lenacapavir is a twice-yearly injectable capsid inhibitor. This is a completely new drug class that targets HIV at multiple stages of its life cycle, including capsid assembly, disassembly, and nuclear transport. Its pharmacology is particularly remarkable because one subcutaneous injection maintains protective drug levels for up to six months, reducing the adherence gaps that often contribute to new infections. It shows just how far innovation has come, moving from daily pills to drugs that sit in the body and offer long-term protection.

To appreciate why it’s getting global attention, it helps to understand what lenacapavir actually is, how it works, and why policy and access conversations are just as important as the science behind it.

(Source: WHO page on Instagram)

What Is Lenacapavir?

Lenacapavir is a capsid inhibitor, a completely new class of antiretroviral drugs, that target enzymes like reverse transcriptase, integrase, or protease. It binds to the HIV capsid, the protein shell that surrounds the viral RNA. This mechanism allows it to interfere with multiple stages of HIV’s life cycle, and because of this multi-stage activity, lenacapavir shows no in vitro cross-resistance with many existing drug classes. This makes it a valuable option both for prevention and for treating individuals with multi-drug-resistant HIV.

Effectiveness Based on Clinical Trial Data

Lenacapavir’s performance in clinical trials has been exceptional. In PURPOSE 1, a randomized study among cisgender women and adolescent girls (a population with some of the highest HIV incidence rates globally) especially in sub-Saharan Africa, zero new HIV infections were recorded among participants receiving twice-yearly lenacapavir injections. This protection was sustained across thousands of person-years of follow-up.

Also, Gilead’s broader Phase 3 PrEP program, which included various populations such as men who have sex with men, transgender women, and people who inject drugs, data reported ≥ 99.9% of participants on Yeztugo (lenacapavir for PrEP) remained HIV-negative. Only a small number of infections occurred, largely in cases where injections were missed, diagnosis was delayed, or participants were already infected at baseline.

These findings represent some of the highest efficacy outcomes ever observed for an HIV prevention intervention, showing lenacapavir’s potential to significantly reduce HIV incidence, especially in high-risk populations.

Global Access & Policy Considerations

While the scientific innovation behind lenacapavir is groundbreaking, its public health impact depends critically on access, policy, and health system readiness. The conversation cannot stop at scientific excitement. WHO guidelines are evolving, and countries considering lenacapavir for national PrEP programs must address policy, pricing, and equitable distribution. High-burden countries, especially across Africa, will need strong procurement strategies, strategic financing partnerships with organizations such as the Global Fund and PEPFAR, and clear implementation frameworks to ensure that lenacapavir reaches those who need it most.

The technical realities also introduce new programmatic considerations. Health systems will need to update HIV testing protocols, strengthen screening procedures, maintain timely injection schedules, and train providers in safe administration and pharmacovigilance. Without these measures, there is a significant risk of drug resistance if someone acquires HIV during the period of declining drug levels.

Without affordable pricing strategies and clear procurement pathways, lenacapavir risks remaining a high-income-country innovation instead of the global solution it aims to be.

Limitations & Challenges

• Missed doses present clinical and programmatic challenges due to the long pharmacologic tail.
• Cost and sustainability remain significant barriers in low-resource settings.

It is not a cure, it prevents infection or treats resistant HIV, but does not eradicate the virus.

Why Lenacapavir Is a Big Deal

• Convenience: Only two injections per year which could transform adherence dynamics.
• High efficacy: Trial results show near-zero infection rates.
• New mechanism: Introduces an entirely new drug class with broad utility.
• Scalability potential: If access challenges are addressed, it could dramatically reduce global HIV incidence.

(Source: WHO page on Instagram)

Conclusion

Lenacapavir represents the convergence of advanced biomedical science and health systems policy. Its efficacy is undeniable, but its true impact will depend on policy alignment, sustainable financing, equitable rollout, and integration into existing HIV prevention frameworks. If these elements come together, lenacapavir has the potential to become a global turning point in HIV prevention, not just another impressive innovation with limited reach.